Finny logo
Finny logo
Dibs:
Dibs:
0

Global Blood Therapeutics (GBT) earnings: expect -8% EPS decline

4:04 am ET, 05 May 2019

Global Blood Therapeutics, Inc. (GBT) is announcing earnings on May 06. Wondering what revenue and earnings will look like?

What should you expect from the upcoming earnings?

Earnings per share are expected to come in at $-0.94. If this materializes, EPS will decline -8% year-over-year.

How did the stock do last month?

Over the last month, Global Blood Therapeutics, Inc. (GBT) returned +7.84%.

What do analysts say about the stock?

Global Blood Therapeutics, Inc. (GBT) average analyst price target is 58.57% above its current price ($55.40).

For the latest price and information on Global Blood Therapeutics, Inc., please visit Finstead and ask for "GBT", "GBT analysis" or "GBT news".

Powered by Froala Editor

Global Blood Therapeutics, Inc. (GBT) Stock Guide

Updated at: 9:59 pm ET, 17 Sep 2020

Before we start: if you're looking for GBT stock price, you can quickly find it out by visiting Finny and typing "GBT quote". If you're looking for a quick scoop on GBT stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "GBT". You'll get all this info in one place. Or you can just type "GBT news" to get the latest stock news.

Looking to buy or sell Global Blood Therapeutics, Inc. (GBT)? Interested in getting the full scoop on GBT, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this GBT stock guide, we'll address key questions about GBT, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are GBT earnings?
2. What is GBT stock forecast (i.e., prediction)?
3. GBT buy or sell? What is GBT Finny Score?
4. What are the reasons to buy GBT? Why should I buy GBT stock?
5. What are the reasons to sell GBT? Why should I sell GBT stock?
6. What are GBT key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are GBT earnings?

GBT trailing 12-month earnings per share (EPS) is -$4.73.

Analyst Predictions

2. What is GBT stock forecast (i.e., prediction)?

Based on GBT analyst price targets, GBT stock forecast is $110.44 (for a year from now). That means the average analyst price target for GBT stock is $110.44. The prediction is based on 13 analyst estimates.

The low price target for GBT is $64.00, while the high price target is $152.00.

GBT analyst rating is Buy.

Analysis

3. GBT buy or sell? What is GBT Finny Score?

#{finnyScore:60}Our quantitative analysis shows 3 reasons to buy and 2 reasons to sell GBT, resulting in Finny Score of 60.

4. What are the reasons to buy GBT? Why should I buy GBT stock?

Here are the reasons to buy GBT stock:

5. What are the reasons to sell GBT? Why should I sell GBT stock?

Let's look at the reasons to sell GBT stock (i.e., the bear case):

  • GBT short share of float is 17.13%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock. See GBT short share of float chart.
  • GBT short interest (days to cover the shorts) ratio is 13.37. The stock garners more short interest than the average industry, sector or S&P 500 stock. See GBT short interest ratio chart.

Key Stats

6. What are GBT key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for GBT:

Metrics GBT
Price $53.44
Average Price Target / Upside $110.44 / 106.66%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 171
Market Cap $3.77B
Forward P/E Ratio -47.67
Price/Book Ratio 79.07
Revenue (TTM) $47.73M
YoY Quarterly Revenue Growth N/A
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us